Primary hypercholesterolemia
Elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apo B protein (Apo B), and triglyceride (TG) in patients with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia. ) and as an adjunct to diet to reduce non-HDL-cholesterol and increase HDL-cholesterol (HDL-C).
Homozygous Familial Hypercholesterolemia (HoFH) Other lipid-lowering treatments (e.g., LDL-Apheresis) to reduce elevated total cholesterol and LDL-cholesterol in patients with homozygous familial hypercholesterolemia (HoFH).
Administer this drug as an adjuvant, or when other lipid-lowering treatments are not useful. It has not been established that the benefit of atorvastatin outweighs the effect of atorvastatin in reducing cardiovascular morbidity and mortality. This drug has not been studied in Fredrickson types I, III, IV, and V of dyslipidemia.
Many risk factors must be considered when administering lipid-modifying drugs to patients at increased risk of arteriosclerotic vascular disease due to hypercholesterolemia. Lipid-control drugs should be used in conjunction with an appropriate diet (including restriction of saturated fat and cholesterol) and when the response to diet and other non-pharmacological measures is insufficient (see '15 of 'Precautions for Use'). Others, refer to the ‘Dyslipidemia treatment guideline (NCEP ATP III Guideline summary table)’ section).
Before administering this drug, other secondary causes of dyslipidemia (e.g. diabetes, hypothyroidism, obstructive liver disease, chronic renal failure, drugs that increase LDL-cholesterol and drugs that reduce HDL-cholesterol [progestin, anabolic steroid) , and corticosteroid]) should be checked, and secondary causes should be treated if necessary. Lipid testing should include total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides. If the triglyceride level is more than 400 mg/dL (more than 4.5 mmol/L), the LDL-cholesterol concentration must be measured by ultracentrifugation. If you are hospitalized for an acute coronary accident, lipids should be measured upon admission or within 24 hours after admission. This measurement can be used as a reference in starting LDL-lowering treatment before or upon discharge of the patient.
2) Usage, dosage
This drug is administered once daily, regardless of meal.
Patients before or while taking this drug must continue to follow a standard cholesterol-lowering diet.
The dosage of this drug should be adjusted according to the patient's baseline LDL-cholesterol level, recommended treatment goal, and patient response.
Primary hypercholesterolemia The dosage range of this drug is 10/10mg to 10/80mg per day. The recommended initial dose is 10/10mg or 10/20mg per day. For patients requiring greater LDL-cholesterol reduction (more than 55%), an initial dose of 10/40 mg per day is recommended. After starting this drug or titrating the dose, check the blood lipid level at intervals of 2 weeks or more and adjust the dose accordingly.
Homozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemia
The recommended dose for patients is 10/40mg or 10/80mg per day. This drug is administered as an adjunct to other lipid-lowering treatments (e.g., LDL-Apheresis) or when other lipid-lowering treatments are not useful.
3) Packaging unit
30 tablets (10 tablets/PTP
